Jon Stoessl
#92,937
Most Influential Person Now
Researcher
Jon Stoessl's AcademicInfluence.com Rankings
Jon Stoesslbiology Degrees
Biology
#8810
World Rank
#11942
Historical Rank
Neuroscience
#1244
World Rank
#1288
Historical Rank
Jon Stoesslphilosophy Degrees
Philosophy
#12471
World Rank
#17323
Historical Rank
Logic
#9320
World Rank
#11796
Historical Rank
Download Badge
Biology Philosophy
Jon Stoessl's Degrees
- Doctorate Medicine University of British Columbia
- PhD Neuroscience University of British Columbia
Why Is Jon Stoessl Influential?
(Suggest an Edit or Addition)According to Wikipedia, Alexander Jon Stoessl is a Canadian neurologist and Parkinson's disease researcher. He is the director of the Pacific Parkinson's Research Centre and Parkinson's Foundation Centre of Excellence at the University of British Columbia . He is also the head of the division of neurology at this university. He is currently the President of the World Parkinson Coalition.
Jon Stoessl's Published Works
Number of citations in a given year to any of this author's works
Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author
Published Works
- The design and performance of IceCube DeepCore (2012) (270)
- Ten‐year follow‐up of Parkinson's disease patients randomized to initial therapy with ropinirole or levodopa (2007) (249)
- The PARK8 locus in autosomal dominant parkinsonism: confirmation of linkage and further delineation of the disease-containing interval. (2004) (207)
- Multimessenger observations of a flaring blazar coincident with high-energy neutrino IceCube-170922A (2018) (174)
- PET study of [(18)F]6-fluoro-L-dopa uptake in neuroleptic- and mood-stabilizer-naive first-episode nonpsychotic mania: effects of treatment with divalproex sodium. (2002) (119)
- Dopamine turnover increases in asymptomatic LRRK2 mutations carriers (2010) (107)
- Supplement 4: Canadian Guidelines on Parkinson's Disease (2012) (100)
- SEARCH FOR TIME-INDEPENDENT NEUTRINO EMISSION FROM ASTROPHYSICAL SOURCES WITH 3 yr OF IceCube DATA (2013) (91)
- Changes of Dopamine Turnover in the Progression of Parkinson's Disease as Measured by Positron Emission Tomography: Their Relation to Disease-Compensatory Mechanisms (2004) (83)
- Molecular imaging to track Parkinson's disease and atypical parkinsonisms: New imaging frontiers (2017) (82)
- Age-related differences in levodopa dynamics in Parkinson's: implications for motor complications. (2006) (76)
- Autoradiographic visualization of NK-3 tachykinin binding sites in the rat brain, utilizing [3H]senktide (1990) (75)
- Intracerebral haemorrhage and angiographic beading following ingestion of catecholaminergics. (1985) (68)
- The NK‐3 tachykinin receptor agonist senktide elicits 5‐HT‐mediated behaviour following central or peripheral administration in mice and rats (1988) (67)
- Behavioural effects of selective tachykinin agonists in midbrain dopamine regions (1991) (57)
- Cosmic-ray antinuclei as messengers of new physics: status and outlook for the new decade (2020) (52)
- Localization of striatal and nigral tachykinin receptors in the rat (1994) (51)
- Absence of mutations in superoxide dismutase and catalase genes in patients with Parkinson's disease. (1995) (44)
- Effects of ageing on the behavioural responses to dopamine agonists: decreased yawning and locomotion, but increased stereotypy (1989) (43)
- Synthesis of thromboxane B2 and prostaglandins by bovine gastric mucosal microsomes. (1977) (42)
- Pharmacological characterization of the behavioral syndrome induced by the NK-3 tachykinin agonist senktide in rodents: evidence for mediation by endogenous 5-HT (1990) (41)
- Senktide, a selective neurokinin B-like agonist, elicits serotonin-mediated behaviour following intracisternal administration in the mouse (1987) (38)
- Environmental Exposures in Elderly Canadians With Parkinson’s Disease (1995) (32)
- Effect of Dopamine Loss and the Metabolite 3-O-Methyl-[18F]Fluoro-dopa on the Relation between the 18F-Fluorodopa Tissue Input Uptake Rate Constant Kocc and the [18F]Fluorodopa Plasma Input Uptake Rate Constant Ki (2003) (30)
- Habitual exercisers versus sedentary subjects with Parkinson's Disease: Multimodal PET and fMRI study (2018) (29)
- Positron emission tomography in pallido-ponto-nigral degeneration (PPND) family (frontotemporal dementia with parkinsonism linked to chromosome 17 and point mutation in tau gene). (2001) (29)
- DCTN1 p.K56R in progressive supranuclear palsy. (2016) (27)
- A kappa opioid antagonist blocks sensitization in a rodent model of Parkinson's disease (1997) (27)
- IceCube sensitivity for low-energy neutrinos from nearby supernovae (vol 535, pg A109, 2011) (2014) (25)
- The opiate antagonist naloxone suppresses a rodent model of tardive dyskinesia (1993) (25)
- Effects of neurotensin in a rodent model of tardive dyskinesia (1995) (23)
- Quantification of Neurological Blood-Based Biomarkers in Critically Ill Patients With Coronavirus Disease 2019 (2020) (22)
- Dopamine D1 receptor agonist-induced grooming is blocked by the opioid receptor antagonist naloxone. (1994) (20)
- Analysis of Four Dopaminergic Tracers Kinetics Using Two Different Tissue Input Function Methods (2000) (19)
- Potential therapeutic targets for Parkinson's disease. (2008) (19)
- Chronic neuroleptic-induced mouth movements in the rat: suppression by CCK and selective dopamine D1 and D2 receptor antagonists (2004) (17)
- Effects of intrastriatal infusion of D2 receptor antisense oligonucleotide on apomorphine‐induced behaviors in the rat (1997) (17)
- Neurotensin and neurotensin analogues modify the effects of chronic neuroleptic administration in the rat (1991) (17)
- Effects of subthalamic nucleus lesions in a putative model of tardive dyskinesia in the rat (1996) (16)
- Effects of ageing on tachykinin function in the basal ganglia (1993) (16)
- Pharmacological characterization of grooming induced by a selective NK-1 tachykinin receptor agonist (1995) (15)
- Peptide-dopamine interactions in the central nervous system: implications for neuropsychiatric disorders (1989) (15)
- Cosmic antihelium-3 nuclei sensitivity of the GAPS experiment (2020) (14)
- Apomorphine-induced yawning in rats is abolished by bilateral 6-hydroxydopamine lesions of the substantia nigra (2004) (14)
- Behavioural evidence for cholecystokinin-dopamine D1 receptor interactions in the rat. (1996) (9)
- What does it mean to be ‘ amyloid-positive ’ ? (2015) (9)
- Liquid Xenon Detectors for Positron Emission Tomography (2011) (9)
- The NK-3 tachykinin agonist senktide elicits yawning and chewing mouth movements following subcutaneous administration in the rat. Evidence for cholinergic mediation (2004) (8)
- Effect of Population k2 Values in Graphical Estimation of DV Ratios of Reversible Ligands (2001) (7)
- Dementia in Movement Disorders (1986) (7)
- Editors' Note: The 200th Anniversary of the Shaking Palsy (2017) (7)
- The Neurotensin Antagonist SR 48692 Fails to Modify the Behavioural Responses to a Dopamine D1 Receptor Agonist in the Rat (1997) (6)
- Impact of the spatial normalization template and realignment procedure on the SPM analysis of [11C]Raclopride PET studies (2004) (6)
- High energy astrophysical neutrino flux characteristics for neutrino-induced cascades using IC79 and IC86-string IceCube conf (2016) (6)
- The antinucleus annihilation reconstruction algorithm of the GAPS experiment (2021) (5)
- High Energy Astrophysical Neutrino Flux Characteristics for Neutrino-induced Cascades Using IC 79 and IC 86-String IceCube Configurations (2015) (5)
- CCCDTD5: Clinical role of neuroimaging and liquid biomarkers in patients with cognitive impairment (2021) (5)
- Effects of graft-derived dopaminergic innervation on the target neurons of patch and matrix compartments of the striatum (1997) (5)
- Neuroleptic-induced chewing movements in the rat are suppressed by peripherally but not centrally administered CCK and abolished by bilateral subdiaphragmatic vagotomy (1993) (5)
- Effects of ethanol in a putative rodent model of tardive dyskinesia (1996) (5)
- Potential therapeutic targets for Parkinson's disease (2008) (5)
- Sensitivity of the GAPS experiment to low-energy cosmic-ray antiprotons (2022) (4)
- Which dopamine receptor(s) do we need for motor function? Lessons from gene targeting and translational blockade. (1996) (4)
- In Search of Cosmic-Ray Antinuclei from Dark Matter with the GAPS Experiment (2021) (4)
- Neuroreceptor imaging: new developments in PET and SPECT imaging of neuroreceptor binding (including dopamine transporters, vesicle transporters and post synaptic receptor sites). (1998) (4)
- Reconstruction of antinucleus-annihilation events in the GAPS experiment (2021) (4)
- Behavioural evidence for CNS tachykinin-cholinergic interactions (1988) (4)
- An Indirect Dark Matter Search Using Cosmic-Ray Antiparticles with GAPS (2018) (3)
- The role of NK-3 and NK-4 receptors in the mediation of reciprocal hindlimb scratching induced by tachykinin receptor agonists (1988) (3)
- Searching for cosmic antihelium nuclei with the GAPS experiment (2021) (3)
- Impact of different realignment algorithms on the SPM analysis of [/sup 11/C]raclopride PET studies (2002) (2)
- Measuring the BP of Four Dopaminergic Tracers Utilizing a Tissue Input Function (2001) (2)
- Event reconstruction performance with the GAPS experiment (2019) (2)
- Phosphorus 31 magnetic resonance spectroscopy in patients with Huntington disease. (1997) (2)
- Cholinergic and striatal dopaminergic dysfunction using pet as a risk marker for developing a neurodegenerative disease in patients with idiopathic rapid eye movement sleep behaviour disorder (2013) (2)
- Comparison between the B max/Kd Plasma Input and Tissue Input Derived Estimates of in DTBZ Studies of Parkinson's (1998) (2)
- Muon track reconstruction and veto performance with D-Egg sensor for IceCube-Gen2 (2017) (1)
- Age dependence of 18F-fluorodopa uptake rate and dopamine turnover PET markers and implications for Parkinson's disease progression (2005) (1)
- Prevention and Management of Late Stage Complications in Parkinson’s Disease (1992) (0)
- GAPS, low-energy antimatter for indirect dark-matter search (2018) (0)
- Correlation between clinical findings and 6 fluorine 18 fluorodopa pets in parkinson's disease (1987) (0)
- Pharmacological characterization of central tachykinin: 5-HT interactions (1988) (0)
- Risk-Promoting Effects of Reward-Paired Cues in Human Sign- and Goal-Trackers (2021) (0)
- Muon track reconstruction and veto performance (2017) (0)
- CJN volume 27 issue S1 Cover and Front matter (2000) (0)
- 2.012 Perry's syndrome is a unique TDP-43 proteinopathy (2007) (0)
- Neural Networks approach to event reconstruction for the GAPS experiment (2021) (0)
- Year Excellence in Education Excellence in Basic Science Research Excellence in Clinical or Applied Research Service to the University & Community Overall Excellence Outstanding Contributions by a Senior Faculty Member Overall Excellence - Early Career Overall Excellence - Senior Faculty (2015) (0)
- GAPS: A New Cosmic Ray Anti-matter Experiment (2018) (0)
- Search for Dark Matter signatures from cosmic-ray antinuclei with the GAPS experiment (2022) (0)
- O.013 Imaging non-motor symptoms of PD (2009) (0)
- Neuroimaging for Disorders of Consciousness: Ethical Priorities in Research, Policy, and Translation (2015) (0)
- The Utility of Blood Based Biomarkers in Detecting Neurological Complications of COVID‐19 in Critically Ill Patients (2022) (0)
- 3.118 Investigation of the role of expectation in the mechanism of the placebo effect in Parkinson's disease using high-resolution positron emission tomography (PET) with [11C] raclopride (2007) (0)
- AGE-RELATED DOPAMINE-DEPENDENT DISORDERS. 1995. Edited by M. Segawa and Y. Nomura. Published by Karger. 256 pages. $C250.00 (1996) (0)
- 3.013 Investigation of the role of expectation in the mechanism of the placebo effect in Parkinson's disease using high-resolution positron emission tomography (PET) with [11C] raclopride (2007) (0)
- 2.115 Perry's syndrome is a unique TDP-43 proteinopathy (2007) (0)
- Bezaed review dyskinesia 2015 progr neurobiol (2015) (0)
- Neuropeptide Y Y1 and Y2 receptor binding in the rat brain after antisense or missense oligodeoxynucleotide treatment (1997) (0)
- Large-scale detector testing for the GAPS Si(Li) Tracker (2023) (0)
- Raul de la Fuente-Fernandez, February 22, 1959-May 11, 2016. (2016) (0)
- 2.027 FUNCTIONAL IMAGING OF NIGROSTRIATAL DOPAMINERGIC SYSTEM WITH POSITRON EMISSION TOMOGRAPHY IN ADULT-ONSET DYSTONIA-PARKINSONISM (PARK14) DUE TO PLA2G6 MUTATION (2012) (0)
- Cosmic Antiproton Sensitivity for the GAPS Experiment (2021) (0)
- GAPS: Searching for Dark Matter using Antinuclei in Cosmic Rays (2019) (0)
This paper list is powered by the following services:
Other Resources About Jon Stoessl
What Schools Are Affiliated With Jon Stoessl?
Jon Stoessl is affiliated with the following schools:
